tbuckley/cabot-search huggingface dataset:
Treating gastro-oesophageal cancer- a national comparison
Authors: S. F. Neong, J. Deacon, I. R. Sargeant, D. L. Morris
Journal: Gut (2011)

<h3>Introduction</h3> The incidence of gastric cancer is on decline but cases of oesophageal adenocarcinoma and junctional tumour are rising in UK. Patients present at a late stage, often preventing treatment with curative intent. A multidisciplinary approach is crucial in the management of these patients- primary chemoradiotherapy being the preferred treatment in squamous cell carcinoma. <h3>Methods</h3> This retrospective study looked into the different treatment modalities in all 373 patients diagnosed with gastro-oesophageal cancers over the 5-year period from 1 January 2004 to 31 December 2008. Between the 2 district general hospitals in our NHS Trust, we cover a catchment population of 500 000. Data were obtained from endoscopy reports, computerised notes of the multidisciplinary team (MDT) meetings and patients9 medical notes. <h3>Results</h3> 139 and 234 patients were diagnosed with gastric and oesophageal cancer respectively over the 5-year period. 66% (245) of them were male. Oesophageal biopsies revealed 149 cases of adenocarcinoma and 69 cases of squamous cell carcinoma. Mean age of diagnosis of oesophageal cancer was 73 (43–93) and 76 (40–95) for gastric cancer. Staging modality of choice includes computerised tomography (CT) scans, positron emission tomography (PET) scans and endoscopic ultrasound (EUS) in selected patients. All of our patients had staging CT. 52 (22%) patients with oesophageal cancer underwent Ivor Lewis oesophagectomy (10 without neoadjuvant chemotherapy) and 19 (8%) patients had primary chemoradiotherapy as their mode of treatment. 1 patient had Halo treatment. For gastric cancer, 45 (32%) patients underwent partial/total gastrectomy with curative intent. The remainder had palliative surgical and/or oncological treatment as well as endoscopic therapy including stenting, dilatation and laser recannulation. <h3>Conclusion</h3> Only a third (33% for gastric cancer and 30% for oesophageal cancer) of all patients diagnosed with gastro-oesophageal cancers in 2004–2008 had curative treatment. Our findings mirror the figures in the recently published National Oesophago-Gastric Cancer Audit 2010 where overall, 36% of patients had curative treatment. The majority of our patients with gastric cancer (66%) were treated palliatively compared to 50% nationally. The number of patients treated with curative intent appears to be waning partly due to the increased use of PET scans and EUS in identifying more advanced disease.
Abstract SY38-02: Molecular oncogenesis of human T-cell lymphoma: Common features with myeloid malignancies
Authors: Olivier A. Bernard
Journal: Cancer Research (2012)

Abstract T-cell lymphomas are a heterogeneous group of diseases associated with poor outcome whose molecular bases are ill characterized. Prompted by the effect of Tet2 inactivation in lymphoid differentiation and the co occurrence of lymphoma in patients with myeloid neoplasm with TET2 mutations, we uncovered TET2 mutations in 2% of B-cell lymphoma and 11% of T-cell lymphoma samples. The highest frequency of TET2 mutation in T-cell lymphoma was observed in the ImmunoAngioblastic (AITL) (10/30: 30%) and the Peripheral T-cell lymphoma, Not otherwise specified (PTCL, NOS) (6/30:20%) subtypes. Cellular analyses showed that TET2 mutations in AITL patients may also be observed in CD34+ hematopoietic progenitors able to differentiate along the myeloid lineages, indicating that TET2 mutations may have occurred in an immature progenitor able to differentiate along both lymphoid and myeloid lineages. Current data indicate that TET2 participate to the control of DNA methylation, through the oxydation of methylcytosine, and therefore the epigenetic control of transcription. Further candidate gene sequencing showed DNMT3A mutations in 11% of T-cell lymphoma samples. In our series, DNMT3A mutations were significantly associated with the presence of TET2 mutations since 8 of the 11 DNMT3A mutated patients also carried a TET2 mutation. In some DNMT3A-mutated-patients, those mutations could be observed during an MDS phase, which had preceded the lymphoma phase. Our data point at transformation pathways common to T-cell lymphoma and myeloid neoplasms. They suggest deregulation of DNA methylation and and provide a further basis for the molecular classification of T-cell lymphomas. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr SY38-02. doi:1538-7445.AM2012-SY38-02
Abstract 1665: Selection of potential responders to FOLFOX therapy in advanced stage colorectal cancer
Authors: Yutaka Midorikawa, Shingo Tsuji, Takao Takahashi, Koichi Yagi, Takao Mamiya, Tadatoshi Takayama, Kazuhiro Yoshida, Yasuyuki Sugiyama, Hiroyuki Aburatani
Journal: Cancer Research (2010)

Abstract Combinations of oxaliplatin combined with various schedules of antimetabolite 5- fluorouracil and leucovorin (FOLFOX) have been the first-line treatment for unresectable colorectal cancer (CRC) and survival benefits for the patients undergoing FOLFOX therapy were demonstrated. That is, the median duration of survival for the group treated with FOLFOX has been reported to be about 20 months, compared with 8 months for the best supportive care group. However, the rate of effect is not so high and has been reported to be approximately 50%. Molecular characterization gene expression profiling will undoubtedly improve the prediction of treatment responses and ultimately the clinical outcome of cancer patients, which has never been accomplished by conventional clinicopathological classification. To identify responders for FOLFOX therapy, we performed random forest analysis based on gene expression data about 49 unresectable colorectal cancer (CRC) patients. Random forest is a prediction model with the classification accuracy for each sample, outlier measure without additional test set analysis, and contribution for class division of each gene can be created. Through this analysis, predictor genes are selected by decision tree analysis using out-of-bag error estimation, which is repeated from 10,000 to 1,000,000 times, and rate of effect of therapy can be determined individually. Computed tomography was performed for all the patients after 4 course of FOLFOX therapy, and 11 patients were diagnosed as progressive disease (PD), 10 stable disease (SD), and 28 partial response (PR), respectively, i.e., the rate of effect of therapy was 57.1%. Using random forest, we could identify 8 predictor genes of response to FOLFOX therapy, SLC25A30, RPS3A, FZD7, MERTK, HABP4, PFKFB2, KIAA0329, and ZBTB41. Consensus clustering based on these predictor genes could classify tumor samples according to drug sensitivity. Furthermore, in cross validation with out-of-bags method, such predictor genes were available to predict PD, SD, and PR patients with an overall accuracy of 77.7% on average (30.7 to 99.8 %). Thus, we could obtain the individual information about efficacy of chemotherapy by about 20% improvement before therapy. Taken together, random forest analysis on gene expression data for unresectable CRC patients could predict responders for FOLFOX therapy with high accuracy rate, and this prediction can be one of factors of decision making of treatment for the patients with colorectal cancer, which will lead us to personalized therapy. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 1665.
THU0111 T-Cell Subsets in Lymph Node Biopsies of Autoantibody Positive Subjects at Risk of Rheumatoid Arthritis (RA) and Early RA Patients
Authors: T. H. Ramwadhdoebe, J. Hähnlein, K. I. Maijer, J. Boorsma, L. J. van Boven, D. M. Gerlag, P. P. Tak, L. G. M. van Baarsen
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Recent work has shown that systemic autoimmunity precedes inflammation of the synovium of rheumatoid arthritis (RA) patients. Therefore, we analyzed different T cell subsets in lymph node biopsies obtained during the earliest phases of RA to determine their possible contribution to the inflammatory process. <h3>Objectives</h3> To examine the phenotype and functional characteristics of lymph node T cells during different phases of RA. <h3>Methods</h3> Seven individuals with arthralgia but without any evidence of arthritis upon physical examination who were positive for IgM rheumatoid factor (IgM-RF) and/or anti-citrullinated protein antibodies (ACPA; RA risk group) and 7 RA patients (disease duration less than 1 year, naïve for disease-modifying antirheumatic drugs and biologics) were included in the study. All study subjects underwent ultrasound-guided inguinal lymph node biopsy. T-helper (Th)1, cytotoxic T cell (Tc)1, Th2, Tc2, Th17, Tc17 and regulatory T cells (Treg) were analysed by multi-color flow cytometry. Cytokine profiles were determined after stimulation with Phorbol Myristate Acetate (PMA) and Ionomycin in the presence of Brefeldin A and Golgi Stop. We used directly labelled antibodies for CD45, CD3, CD4, CD8, IFN-y (Th1/Tc1), IL-4 (Th2/Tc2), IL-17A (Th17/Tc17), foxp3, and IL-10 (Treg). <h3>Results</h3> The number of IFNy or IL-4 producing CD4+ and CD8+ T cells were on average comparable between the RA risk and early arthritis group. An increase of IL-17A producing CD4 T cells (Th17; p=0.04) and IL-10 producing CD4 T cells (p=0.014) could be observed in the early arthritis group compared to the RA risk group. Interestingly, a significant correlation between ACPA titers and IL-10 producing and IL-17A producing CD4 T cells (r=0.78; p=0.0016 and r=0.54; p=0.048) and between IgM-RF and IL-17A producing CD4 T cells (r=0.57; p=0.04) was found when combining both study groups. Additionally, within the RA risk group the levels of IL-10 producing CD4 T cells correlated significantly with the total tender joint count (TOTTJC28; r=0.8697; p=0.03). <h3>Conclusions</h3> Flow cytometry analysis of lymph node cells suggests an increase in IL-17A and IL-10 producing CD4 T cells in patients with early RA. Moreover, the number of these T cells correlates with autoantibody levels suggesting an important role of these T cells in the humoral autoimmune response. These data indicate that both proinflammatory cytokines as well as regulatory cytokines are increased during the earliest phases of arthritis, suggesting an early change in the immunoregulatory balance. These results provide for the first time new insights in immunological lymph node changes associated with RA pathogenesis. <h3>Disclosure of Interest</h3> None Declared
AB0801 Treatment of chronic ankle sprain with periarticular hyaluronan
Authors: R. Petrella, M. Petrella, J. Decaria
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Ankle sprains are among the most common of all sports injuries yet consensus regarding optimal treatment is lacking. Conservative treatment may limit disability to an average of 8 days for a grade 1 and 15 days for a grade 2 injury. However, failure to provide adequate therapy can limit a patient's efforts in rehabilitation, prolong the recovery period and result in limited return to sport. <h3>Objectives</h3> To determine the efficacy and safety of a single peri-articular injection of Hyaluronan in chronic, unremitting lateral ankle sprain. <h3>Methods</h3> 28 patients (19 males) with unremitting, recurrent second or third degree lateral sprain unresponsive to conventional treatment and with persistent (over 6 months) moderate to severe pain (&gt;45mm on 100 mm pain visual analogue scale /VAS) and failure to return to sport were included. Exclusion criteria included bilateral ankle sprain, ipsilateral knee trauma, or prior intra-or peri-articular ankle injection in the prior 6 months. All patients were university basketball or volleyball players. Screening assessment included a physical exam and an x-ray of the ankle joint to exclude fracture. Treatment included injection (2.8 mL total, 730-1300kDa) delivered during a single penetration along three planes anteroposterior, medial, and lateral to the proximal ligamentous landmark under ultrasound guideance. Assessments at baseline and Days 14, 30, and 90 post injection included VAS (0-10 cm) pain on weight bearing and walking 20 m, patient global assessment of ankle injury (5-point categorical scale), patient satisfaction with treatment (5-point categorical scale) and adverse events. Differences from baseline were determined using an ANOVA. <h3>Results</h3> All patients completed the study. No serious adverse events were reported. A significant reduction from baseline in VAS pain on both weight bearing and walking was observed at Day 30 and 90 (p&lt;0.05; p&lt;0.001 respectively). Patient global assessment and satisfaction with treatment were improved at Day 30 (p&lt;0.01) and Day 90 (p&lt;0.05). One patient exhibited swelling at the injection site and 2 patients reported tenderness at the injection site. <h3>Conclusions</h3> Peri-articular HA treatment for chronic, unremitting ankle sprain was highly satisfactory in the short and long term. This was associated with reduced pain at rest and during weight bearing with few associated adverse events. <h3>Disclosure of Interest</h3> None Declared
AB0631 Efficacy and safety of urine alkalinization for patients with uric acid nephrolithiasis with or without gout arthritis:. a systematic review
Authors: F. Teixeira, J. Rovisco, S. Ramiro, J. Branco, R. Buchbinder
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Gout is a complex metabolic and inflammatory disease with <i>varying clinical presentations including gouty arthritis, uric acid nephrolithiasis and renal impairment.</i> Urine alkalinization may be a useful adjunct in the management of gout. As part of the 3e initiative for generating recommendations for the diagnosis and management of gout, we performed a systematic review using Cochrane methods to determine the efficacy and safety of urine alkalinization in patients with uric acid nephrolithiasis with or without gouty arthritis. <h3>Objectives</h3> Determine the efficacy and safety of urine alkalinization in patients with uric acid nephrolithiasis with or without gouty arthritis. <h3>Methods</h3> We searched Medline, EMBASE and Cochrane databases to March 2012, and 2010-11 ACR/EULAR abstracts to identify all randomized controlled trials (RCTs) and quasi-RCTs that compared urine alkalinization to placebo or another therapy in people with uric acid nephrolithiasis with or without gouty arthritis. Primary outcomes were uric acid stone regression and withdrawals due to adverse effects. Two review authors independently selected studies for inclusion, assessed risk of bias (RoB) and extracted data using Cochrane methods. <h3>Results</h3> A total of 7103 articles were identified, of which 76 articles were selected for detailed review and two fulfilled inclusion criteria. One trial (60 participants) was judged to be at low risk of bias (RoB) and compared potassium citrate to phytotherapy. At 12 weeks, 14/30 (47%) people who received potassium citrate achieved uric acid stone remission compared to 9/30 (30%) in the phytotherapy group (P=0.05). The other trial (191 participants) was judged to be at unclear RoB and compared four treatment arms: potassium citrate and tamsulosin versus placebo or potassium citrate or tamsulosin. At 4 weeks, 27/46 (59%) who received potassium citrate achieved stone remission compared to 12/46 (26%) in the placebo group (P=0.003). There were no withdrawals in either trial due to adverse events. <h3>Conclusions</h3> There is limited evidence from two trials (1 at low RoB and 1 at unclear RoB) that urine alkalinization may be an efficacious and safe treatment for patients with uric acid nephrolithiasis with or without gouty arthritis. <h3>Disclosure of Interest</h3> None Declared
Potassium-Depletion Syndrome Secondary to Nephropathy Apparently Caused by Outdated Tetracycline
Authors: Milford Fulop, Arnold Drapkin
Journal: New England Journal of Medicine (1965)

A SYNDROME of temporary renal dysfunction apparently caused by ingestion of deteriorated tetracycline has been reported in 6 patients during the past year and a half.1 2 3 4 5§ Glycosuria, aminoaciduria and phosphaturia were prominent, and proteinuria occurred in all the patients. Acidosis was common, and nitrogen retention and hypokalemia were sometimes observed.In the 2 cases presented below, potassium depletion was a remarkable feature of the illness. Serial renal biopsies were performed in 1 patient.Case ReportsCase 1. V.K. (B.M.H.C. 202371), the 22-year-old sister-in-law of a physician, was hospitalized on November 13, 1962, complaining of severe weakness and lethargy of 10 . . .
Reply to Conio et al.
Authors: F. van Vilsteren, J. Bergman
Journal: Endoscopy (2013)

We thank Dr. Conio and colleagues for their comments on our study. Our study showed that circumferential balloon-based radiofrequency ablation (c-RFA) and endoscopic resection in a single session is feasible in patients with Barrett’s esophagus containing early neoplasia in the setting of an expert center [1]. Complete response for neoplasia was achieved in all 20 patients (100 %) and complete response for intestinal metaplasia was achieved in 19 of 20 patients (95 %) in a per protocol analysis. The intention-to-treat analysis included four additional patients who did not finish treatment due to unrelated disease (n = 2) or who underwent curative surgery as they were not eligible for further endoscopic treatment after initial (staging) endoscopic resection (n = 2). Based on our results, we advise that endoscopic resection followed by RFA after 6 – 8 weeks remains the standard treatment protocol for the combined use of endoscopic resection and RFA for early Barrett’s neoplasia for the majority of cases [1] [2]. Single-session c-RFA and endoscopic resection should be reserved for selected patients with large lesions or those at high risk for stenosis.
THU0032 Fibromyalgia Prevalence and Related Factors in A Large Spanish Cohort of Patients with Systemic Lupus Erythematosus: Table 1.
Authors: T. Salman-Monte, V. Torrente-Segarra, I. Rúa-Figueroa, J. Pego-Reigosa, F. Lόpez-Longo, M. Galindo, J. Calvo-Alén, S. Pérez Vicente
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Systemic lupus erythematosus (SLE) is an autoimmune disease that may affect multiple organs. Fibromyalgia (FM) is a physical, mental and social impairing disease. FM has been observed in SLE patients. The objective of this study is to determine the prevalence of FM in SLE patients, and to study its association to depression and other SLE-related factors. As has been previously described, FM looks to be more frequent in long-term SLE than in early SLE stages. <h3>Methods</h3> A cross-sectional data analysis from RELESSER-T Spanish registry, which includes SLE patients in a National multicenter retrospective charts review. Inclusion criteria: SLE patients who fulfilled ≥4 ACR-SLE diagnostic criteria. We divided them into 2 groups: ≤5 years of SLE duration, and &gt;5 years of SLE duration. Main variables were FM. Depression, sociodemographics, comorbidities, active SLE symptoms, serological markers, therapies and different indexes to assess the status of the disease. Descriptive, associative and logistic regression statistical analyses were performed. <h3>Results</h3> We selected 3,679 SLE patients. A total of 3,229 (90.1%) were women, with a mean age at the time of diagnosis of 34.6 (SD 14.6) years old. A total of 93.1% were Caucasians. FM prevalence was 6.2%, being higher in those with SLE duration longer than five years (6.9% vs 4%) (p&lt;0,05). SLE-FM patients showed higher prevalence of Depression (53.1% vs 14.6%) (p&lt;0,05). Adjusting by risk factors: comorbidities, age, SLE disease duration time and mean highest steroids dosage, the risk of suffering depression in FM-SLE patients is 7.295 (CI 5.180-10.274) (p&lt;0,05). FM in SLE was inversely associated to the presence of several clinical symptoms, serological markers and activity index scores (Table 1). <h3>Conclusions</h3> FM in Caucasian SLE patients was significantly higher in patients with longer disease duration and in older women. The presence of FM in both groups was strongly associated to the presence of Depression, which showed a 7.2 fold risk association. The main SLE-related related factors were longer disease duration and steroids mean highest daily dosage range 10-30 mg. All this information might help to a better comprehension and therapeutic approach of FM in patients with SLE. <h3>Disclosure of Interest</h3> : None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.2046
Case 39-2009
Authors: Patrick T. O'Gara, Jo-Anne O. Shepard, Kibar Yared, Aliyah R. Sohani
Journal: New England Journal of Medicine (2009)

A 28-year-old woman was admitted to this hospital 2 days post partum because of cardiac failure. Four weeks earlier, at approximately 29 weeks' gestation, retrosternal chest discomfort developed, followed by shortness of breath, myalgias, and fatigue. Echocardiography revealed a pericardial effusion, with tamponade and biventricular hypokinesis. Despite pericardiocentesis and cesarean section at 32 weeks, her condition worsened. Radiographs obtained at this hospital showed a widened mediastinum; echocardiography revealed thickening of the pericardium and abnormal material surrounding the great vessels. A diagnostic procedure was performed.
Brain Metastasis in Carcinoma Breast Demonstrated on 68Ga NOTA-Bisphosphonate PET/CT
Authors: Averilicia Passah, Madhavi Tripathi, Rajeev Kumar, Chandan J Das, Ankur Goyal, Chandrasekhar S Bal
Journal: Clinical Nuclear Medicine (2014)

68Ga NOTA-bisphosphonate is a new bone-seeking PET radiotracer undergoing clinical evaluation. We report a case of a carcinoma breast who underwent 68Ga NOTA-bisphosphonate PET/CT for detection of skeletal metastasis. In addition to skeletal metastasis, a focal area of abnormal radiotracer uptake was noted in the brain, which was confirmed as brain metastasis on MRI.